{"organizations": [], "uuid": "852ac0c2e12b0e79ce219ad2f9057e364660226a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180514.html", "section_title": "Archive News &amp; Video for Monday, 14 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-galectin-therapeutics-proceeds-to/brief-galectin-therapeutics-proceeds-to-phase-3-development-of-gr-md-02-for-nash-cirrhosis-idUSASC0A1ZG", "country": "US", "domain_rank": 408, "title": "BRIEF-Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.156, "site_type": "news", "published": "2018-05-14T21:17:00.000+03:00", "replies_count": 0, "uuid": "852ac0c2e12b0e79ce219ad2f9057e364660226a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-galectin-therapeutics-proceeds-to/brief-galectin-therapeutics-proceeds-to-phase-3-development-of-gr-md-02-for-nash-cirrhosis-idUSASC0A1ZG", "ord_in_thread": 0, "title": "BRIEF-Galectin Therapeutics Proceeds To Phase 3 Development Of GR-MD-02 For NASH Cirrhosis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "galectin therapeutics inc", "sentiment": "negative"}, {"name": "nash", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 14 (Reuters) - Galectin Therapeutics Inc:\n* GALECTIN THERAPEUTICS PROCEEDS TO PHASE 3 DEVELOPMENT OF GR-MD-02 FOR NASH CIRRHOSIS FOLLOWING FDA MEETING\n* GALECTIN THERAPEUTICS INC - TARGET POPULATION OF PHASE 3 CLINICAL TRIAL WILL BE PATIENTS WITH NASH CIRRHOSIS WITHOUT ESOPHAGEAL VARICES\n* GALECTIN THERAPEUTICS INC - “DISAGREE WITH FDA’S DECISION NOT TO GRANT BREAKTHROUGH THERAPY DESIGNATION AT THIS TIME”\n* GALECTIN THERAPEUTICS - FDA HAS NOT GRANTED BREAKTHROUGH DESIGNATION FOR PATIENTS WITH NASH CIRRHOSIS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and-landscape-tablet medium-wide-browser-and-larger above-phone portrait-tablet-and-above above-portrait-tablet landscape-tablet-and-above landscape-tablet-and-medium-wide-browser portrait-tablet-and-below landscape-tablet-and-below Apps Newsletters Reuters Plus Advertising Guidelines Cookies Terms of Use Privacy\nAll Quote: s delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.\n© 2018 Reuters. All Rights Reserved.", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-14T21:17:00.000+03:00", "crawled": "2018-05-15T14:16:16.004+03:00", "highlightTitle": ""}